Contergan Victim Wins Against Former Board Member of the Contergan Foundation

Food and Healthcare Press Releases Thursday June 8, 2017 09:32
COLOGNE, Germany--8 Jun--PRNewswire/InfoQuest

In the lawsuit between the plaintiff, Contergan (thalidomide) victim Andreas Meyer, and the defendant and former Board member of the Contergan Foundation, Attorney Karl Schucht, the Bonn Regional Court came to a judgement on 10.5.2017. The judgement is not yet final. The case concerns the question of possible collaboration between Gruenenthal and the Federal German Contergan Foundation.

Meyer was and will be represented by Prof. Dr. Jan Hegemann from the law firm Raue Rechtsanwalte LLP in Berlin.
Please refer the full press release dated 08.06.2017 at: http://www.gruenenthal-opfer.de/press_ContVict_wins_agains_memb_ContFound_8_6_2017
You can read the judgement and further information at the following link:
http://www.gruenenthal-opfer.de/Materials_Judgement_Meyer_vs_Schucht_10_05_2017
Contact:
Federation of Thalidomide Sufferers and Gruenenthal Victims
c/o Mr Andreas Meyer (Chairman)
Dohmengasse 7
50829 Koln
Email: bcg-brd-dachverband@gmx.de
Website: www.gruenenthal-opfer.de
Mobile: +49 (0)172 / 2905974
Source: Federation of Thalidomide Sufferers and Gruenenthal Victims

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics